Celcuity Inc
CELC
Company Profile
Business description
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Contact
16305 36th Avenue North
Suite 100
MinneapolisMN55446
USAT: +1 763 392-0767
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
AMD earnings: Data center demand still looks quite strong to us
AMD has the components to target $100 billion of AI revenue in the next few years.
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.90 | 8.00 | -0.09% |
| CAC 40 | 8,262.16 | 82.66 | 1.01% |
| DAX 40 | 24,603.04 | 177.75 | -0.72% |
| Dow JONES (US) | 49,501.30 | 260.31 | 0.53% |
| FTSE 100 | 10,402.34 | 87.75 | 0.85% |
| HKSE | 26,446.99 | 400.33 | -1.49% |
| NASDAQ | 22,904.58 | 350.61 | -1.51% |
| Nikkei 225 | 53,879.23 | 414.13 | -0.76% |
| NZX 50 Index | 13,476.92 | 9.63 | 0.07% |
| S&P 500 | 6,882.72 | 35.09 | -0.51% |
| S&P/ASX 200 | 8,904.40 | 0.40 | 0.00% |
| SSE Composite Index | 4,060.35 | 41.85 | -1.02% |